Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer (CEPO906AUS10)
Status: Archived
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer (CEPO906AUS10)
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Resveratrol for Patients With Colon Cancer
Resveratrol for Patients With Colon Cancer
Status: Archived
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Resveratrol for Patients With Colon Cancer
Resveratrol for Patients With Colon Cancer
Status: Archived
Updated: 1/1/1970
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Patient Navigator Research Program
Patient Navigator Research Program
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Patient Navigator Research Program
Patient Navigator Research Program
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
Status: Archived
Molokai General Hospital
mi
from
Kaunakakai, HI
Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project
Status: Archived
Updated: 1/1/1970
Molokai General Hospital
mi
from
Kaunakakai, HI
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Stanford University School of Medicine
mi
from
Stanford, CA
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Updated: 1/1/1970
Stanford University School of Medicine
mi
from
Stanford, CA
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients With Metastatic Colorectal Cancer
Status: Archived
Columbia River Oncology Program
mi
from
Portland, OR
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients With Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Columbia River Oncology Program
mi
from
Portland, OR
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients With Metastatic Colorectal Cancer
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients With Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
Phase II Randomized Study of SIR-Spheres, Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Metastases to the Liver
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
Phase II Randomized Study of SIR-Spheres, Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Metastases to the Liver
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memoral Sloan Kettering Cancer Center at Phelps
mi
from
Sleepy Hollow, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memoral Sloan Kettering Cancer Center at Phelps
mi
from
Sleepy Hollow, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Study of Vaginal Dilator Use After Pelvic Radiotherapy
A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening
Evaluating a Preference-based Intervention for Increasing CRC Screening
Status: Archived
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening
Evaluating a Preference-based Intervention for Increasing CRC Screening
Status: Archived
Updated: 1/1/1970
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening
Evaluating a Preference-based Intervention for Increasing CRC Screening
Status: Archived
Center for Health Equity Research and Promotion
mi
from
Pittsburgh, PA
Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening
Evaluating a Preference-based Intervention for Increasing CRC Screening
Status: Archived
Updated: 1/1/1970
Center for Health Equity Research and Promotion
mi
from
Pittsburgh, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
Status: Archived
Ingalls Cancer Research Center
mi
from
Harvey, IL
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Ingalls Cancer Research Center
mi
from
Harvey, IL
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Metastatic Colorectal Cancer
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors Followed by a Randomized Phase II Study of XELOX-A-Ev Compared to Capecitabine, Oxaliplatin, Bevacizumab (XELOX-A) in Subjects With Previously Untreated Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study
Status: Archived
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study
Status: Archived
Updated: 1/1/1970
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study
Status: Archived
University of Chicago
mi
from
Chicago, IL
Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
KRAS Wild-type Metastatic Colorectal Cancer Trial
Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
KRAS Wild-type Metastatic Colorectal Cancer Trial
Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Apollo Overstitch, a Treat and Resect Model
Evaluation of a Novel Endoscopic Suturing Device in a Treat and Resect Model
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Apollo Overstitch, a Treat and Resect Model
Evaluation of a Novel Endoscopic Suturing Device in a Treat and Resect Model
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
Status: Archived
Temple University
mi
from
Philadelphia, PA
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
Status: Archived
Updated: 1/1/1970
Temple University
mi
from
Philadelphia, PA
Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon
Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon
Status: Archived
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon
Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
mi
from
Minneapolis, MN
Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon
Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon
Status: Archived
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon
Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon
Status: Archived
Updated: 1/1/1970
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Denver, CO
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Denver, CO
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Newark, DE
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Newark, DE
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Bronx, NY
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bronx, NY
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Asheville, NC
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Asheville, NC
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Clinical Research Facility
mi
from
Bellingham, WA
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bellingham, WA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Tucson, AZ
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Tucson, AZ
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Alhambra, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Alhambra, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Bakersfield, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bakersfield, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Fullerton, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fullerton, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
La Jolla, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
La Jolla, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Long Beach, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Long Beach, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Orange, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Orange, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Pomona, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Pomona, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Santa Barbara, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Santa Barbara, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Santa Barbara,, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Santa Barbara,, CA